Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Breast Cancer Research
  • View item
  • Home
  • ICR Divisions
  • Breast Cancer Research
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Current status of HER2 testing.

Thumbnail
Date
2002-01
ICR Author
Dowsett, Mitch
Author
Di Leo, A
Dowsett, M
Horten, B
Penault-Llorca, F
Type
Conference Proceeding
Metadata
Show full item record
Abstract
HER2 gene amplification and receptor overexpression by tumors seems to be associated with poorer prognosis and may be predictive of response to certain anticancer therapies. Furthermore, and paramount to the clinician and patient, a positive HER2 status is a prerequisite eligibility requirement for Herceptin (trastuzumab) therapy in women with metastatic breast cancer. As a consequence, issues relating to accurate and reliable laboratory assessment of HER2 status are a matter of significant debate to pathologists and oncologists. Out of a wide range of techniques that have been used in research for the detection of HER2 status, two technologies are now predominant in the routine clinical pathology laboratory: determination of HER2 protein overexpression by immunohistochemistry (IHC) and HER2 gene amplification by fluorescence in-situ hybridization (FISH). This article discusses some of the recent experiences, guidelines, and opinions of pathologists and clinicians concerning aspects of HER2 testing with respect to when to test (at initial diagnosis or pretreatment), the relative advantages/disadvantages of IHC and FISH, and where to test (local or centralized laboratories).
URI
https://repository.icr.ac.uk/handle/internal/2025
DOI
https://doi.org/10.1159/000066204
Collections
  • Breast Cancer Research
  • Molecular Pathology
Subject
Humans
Breast Neoplasms
Receptor, erbB-2
Antineoplastic Agents
Antibodies, Monoclonal
Mass Screening
Disease-Free Survival
Algorithms
Time Factors
Female
Antibodies, Monoclonal, Humanized
Trastuzumab
Research team
Endocrinology
Language
eng
License start date
2002-01
Citation
Oncology, 2002, 63 Suppl 1 pp. 25 - 32

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.